ADXN
NASDAQ
$5.64
Addex Therapeutics Ltd (ADXN)
Addex Therapeutics Ltd, a developing-stage biopharmaceutical company, discovers, develops and markets small molecule pharmaceuticals for central nervous system (CNS) disorders in Switzerland. The company is headquartered in Geneva, Switzerland.
Sector:
Healthcare
Industry:
Biotechnology
Target: $30 (+431.91%)
Market Cap
$8.21M
Free Cash Flow Yield
-35.65%
Beta (5Y)
0.56
Price Chart
Valuation
Market Cap$8.21M
P/S71.50
P/B1.81
Profitability
Total Revenue (TTM)$117K
Gross Profit (TTM)-$553K
EBITDA-$7.76M
Operating Margin-6239%
Financial Health
Debt-to-Equity3.1%
Free Cash Flow Yield-35.65%
Growth & Risk
Revenue 5Y CAGR-50.31%
FCF 5Y CAGR-25.66%
Beta (5Y)0.56
Sharpe Ratio-0.12